IL6 and COVID-19: As monoclonal antibodies against interleukin 6 receptor (IL-6), among which tocilizumab and satralizumab whose pharmacological mechanism is mainly to specifically bind to IL-6 receptor and inhibit its activation, thus inhibiting cytokine storm and reducing mortality (126), clinical studies have also confirmed that the application of this drug has significant efficacy in improving the inflammatory response in patients with COVID-19 (127).